授出購股權詳情 購股權詳情如下： 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeiGene, Ltd. 百濟神州有限公司 （於開曼群島註冊成立的有限公司） （股份代號：06160） 授出購股權及受限制股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2023年11月13 日，董事會薪酬委員會根據2016期權及激勵計劃的條款向二名承授人授出可認購 合共1,869股美國存託股份的購股權並向一百五十三名承授人授出涉及合共42,384 股美國存託股份的受限制股份單位。 2016期權及激勵計劃項下的購股權 於2023年11月13日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予二名 承授人可認購合共1,869股美國存託股份的購股權。 | 授出日期： | 2023年11月13日 | | --- | --- | | 承授人數目： | 二名 | | 已授出購股權涉及 的相關股份數目： | 24,297 | | 購股權總數 ...

Financial Performance - Total revenue for Q3 2023 reached RMB 5,624,008 thousand, representing a 111.5% increase year-over-year[4] - Total revenue for the first three quarters of 2023 reached RMB 12,875,236 thousand, a significant increase from RMB 6,868,770 thousand in the same period of 2022, representing an increase of approximately 87.5%[21] - Net profit attributable to shareholders for the year-to-date period was RMB -3,878,105 thousand, with a basic earnings per share of RMB 0.99 for Q3 2023[4][5] - The diluted earnings per share for Q3 2023 was RMB 0.96, reflecting the impact of non-cash gains from arbitration settlements[10] - The basic and diluted earnings per share for the first three quarters of 2023 were both RMB -2.85, an improvement from RMB -7.80 in the same period of 2022[22] - Net loss for the first three quarters of 2023 was RMB 3,878,105 thousand, an improvement compared to a net loss of RMB 10,433,648 thousand in the same period of 2022, reflecting a reduction of approximately 62.9%[21] Research and Development - Research and development expenses totaled RMB 3,295,174 thousand in Q3 2023, accounting for 58.59% of total revenue, a decrease of 54.32 percentage points compared to the previous year[5][10] - Research and development expenses for the first three quarters of 2023 totaled RMB 9,177,446 thousand, compared to RMB 8,017,379 thousand in 2022, marking an increase of approximately 14.5%[21] Cash Flow and Liquidity - The company reported a net cash flow from operating activities of RMB -5,401,589 thousand for the year-to-date period[5] - Cash flow from operating activities for the first three quarters of 2023 was negative RMB 5,401,589 thousand, compared to negative RMB 6,458,895 thousand in the same period of 2022, showing an improvement of about 16.4%[23] - Cash inflow from operating activities totaled RMB 11,932,632 thousand in the first three quarters of 2023, compared to RMB 10,716,565 thousand in 2022, reflecting an increase of about 11.3%[23] - Cash and cash equivalents decreased from RMB 20,132,630 thousand at the end of 2022 to RMB 17,910,776 thousand[18] - Cash and cash equivalents at the end of the period decreased to $17,827,502 from $27,193,265 year-over-year[24] - Initial cash and cash equivalents balance was $20,111,301, down from $25,875,226 year-over-year[24] Assets and Liabilities - Total assets at the end of the reporting period were RMB 40,191,661 thousand, a decrease of 9.1% compared to the end of the previous year[5] - Total current assets decreased from RMB 36,173,906 thousand at the end of 2022 to RMB 29,591,210 thousand as of September 30, 2023[18] - Total assets decreased from RMB 44,224,173 thousand at the end of 2022 to RMB 40,191,661 thousand as of September 30, 2023[18] - The total liabilities decreased from RMB 13,893,114 thousand in 2022 to RMB 12,878,455 thousand in 2023, a reduction of about 7.3%[21] - The company's total equity attributable to shareholders at the end of the reporting period was RMB 27,313,206 thousand, down 9.9% from the previous year[5] - The total equity attributable to shareholders decreased from RMB 30,331,059 thousand in 2022 to RMB 27,313,206 thousand in 2023, a decline of approximately 10.0%[21] Shareholder Information - The total number of shares issued by the company is 1,376,270,732, with 91.64% of shares issued overseas[11] - Total number of common shareholders at the end of the reporting period was 40,908[12] - Amgen Inc. holds 246,269,426 shares, representing 17.89% of total shares[13] - Baker Brothers Life Sciences, L.P. holds 152,602,311 shares, representing 11.09% of total shares[13] Operational Efficiency - The company experienced a significant increase in product revenue and collaboration income, contributing to improved operational efficiency[9] Government Support - The company received government subsidies amounting to RMB 13,207 thousand during the reporting period[6] Industry Risks - The company emphasizes the high risks and uncertainties in the biopharmaceutical industry, affecting drug development and commercialization[16]

Financial Performance - Total revenue for Q3 2023 reached $781.3 million, a year-over-year increase of 101.6% from $387.6 million in Q3 2022[5] - Total revenue for the third quarter ended September 30, 2023, was $781.308 million, a significant increase from $387.628 million in the same period of 2022, representing a growth of 101.0%[6] - Product revenue for the third quarter was $398.229 million in the U.S., up 198.5% from $133.431 million year-over-year, driven by strong sales of proprietary products[6] - In China, total revenue reached $287.935 million, compared to $233.077 million in the same quarter of 2022, marking a growth of 23.6%[6] - Product revenue, net collaboration revenue for the nine months ended September 30, 2023, was $1.56 billion, compared to $915.6 million for the same period in 2022, marking an increase of 70%[18] - The company reported a net profit of $215.4 million for the third quarter of 2023, a turnaround from a net loss of $557.6 million in the same quarter of 2022[18] - Net profit for the third quarter was $21.54 million, a turnaround from a net loss of $55.76 million in the same quarter of 2022, attributed to reduced operating losses and non-operating income[8] - Basic and diluted earnings per share for the third quarter were $0.16 and $0.15, respectively, compared to a net loss per share of $0.41 in the same period last year[9] Product Development and Approvals - Global product revenue amounted to $595 million, reflecting a 70% year-over-year growth[3] - Global sales of Baiyueze® reached $357.7 million, a 130% increase compared to the same period last year, driven by ongoing global launches for multiple indications[3] - The company regained global rights for BaiZeAn®, which has been approved in the EU and is under regulatory review in 10 other markets[3] - BaiZeAn® received approval from the European Commission for use as a monotherapy in adult patients with unresectable, locally advanced, or metastatic ESCC who have previously received platinum-based chemotherapy[4] - The FDA has accepted a Biologics License Application (BLA) for BaiZeAn® for first-line treatment of unresectable, recurrent, locally advanced, or metastatic ESCC, with a decision expected by July 2024[4] - The company received positive opinions from the CHMP supporting Baiyueze® for treating adult patients with relapsed or refractory follicular lymphoma[3] - The company expects to receive FDA approval for a new indication for Baiyueze® in Q4 2023 based on the PFS efficacy results from the Phase 3 ALPINE trial for R/R CLL/SLL[12] - The company plans to submit a supplemental NDA for Baiyueze® in combination with obinutuzumab for R/R FL adult patients in March 2024, anticipating FDA approval[12] - The company will submit a new indication sBLA for first-line gastric cancer treatment in 2023 and for ESCC in Japan in H1 2024[12] - The company will present long-term follow-up data from the Phase 3 ALPINE trial comparing Baiyueze® to ibrutinib for R/R CLL/SLL at the ASH annual meeting in December 2023[13] Operational Efficiency and Strategy - The company is steadily improving operational leverage while controlling expense growth[3] - The company expects product revenue growth to continue to outpace operating expense growth, leading to sustained operational leverage[7] - The company is advancing its global growth strategy with a focus on enhancing its oncology product portfolio[3] - The company is focused on expanding its drug pipeline and enhancing drug accessibility and affordability for cancer patients globally[19] - Future growth strategies include advancing clinical activities and regulatory submissions for new drug candidates[20] Manufacturing and Capacity - The flagship manufacturing facility in New Jersey is nearing completion and is expected to be operational by summer 2024, with over 1 million square feet reserved for future expansion[15] - The company’s Guangzhou facility has reached a total capacity of 64,000 liters, with ADC production facilities nearing completion[15] - The company is actively working on building production facilities to increase manufacturing capacity and meet future demand[20] Financial Position - Cash, cash equivalents, and short-term investments totaled $3.2 billion as of September 30, 2023, down from $4.5 billion at the end of 2022[9] - The company’s financial summary shows total assets of $5,524,879 thousand as of September 30, 2023, down from $6,379,290 thousand at the end of 2022[17] - Total liabilities decreased to $1,761,645 thousand as of September 30, 2023, compared to $1,995,935 thousand at the end of 2022[17] - Shareholders' equity totaled $3,763,234 thousand as of September 30, 2023, down from $4,383,355 thousand at the end of 2022[17] Collaboration and Partnerships - The company reported a significant increase in deferred revenue related to its collaboration with Novartis, contributing to overall revenue growth[5] - The company terminated a collaboration agreement with Zymeworks for the development and commercialization of a dual-targeting HER2 antibody-drug conjugate in Asia (excluding Japan), Australia, and New Zealand[16] Research and Development Expenses - Research and development expenses for the third quarter of 2023 were $453.3 million, up from $426.4 million in the same quarter of 2022, reflecting a year-over-year increase of 6%[18] Intellectual Property - The management highlighted the importance of maintaining intellectual property protection for its drugs and technologies as a key factor for commercial success[20]

中国国际金融股份有限公司、高盛（中国）证券有限责任公司 关于百济神州有限公司 调整部分募投子项目募集资金投资金额的核查意见 中国国际金融股份有限公司与高盛（中国）证券有限责任公司（以下合称"联 席保荐机构"）作为百济神州有限公司（以下简称"百济神州"或"公司"）首次公开 发行人民币普通股（A股）股票并在科创板上市的联席保荐机构，根据《上市公 司监管指引第2号——上市公司募集资金管理和使用的监管要求（2022年修订）》 《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》《上海证 券交易所科创板股票上市规则》等有关规定，就百济神州为保证公司创新药的研 发进度，提高募集资金使用效率，拟根据药物临床试验研发进展、资金安排对公 司首次公开发行人民币普通股（A股）股票募集资金（以下简称"首次发行募集 资金"）投资项目"药物临床试验研发项目"中包含临床阶段研发项目外部费用、 临床阶段研发项目内部费用、临床阶段研发项目材料费用以及临床前研究费用四 项子项目（以下合称"子项目"）拟投入的募集资金金额进行调整的事项（以下 简称"本次调整"）进行了审慎核查，具体情况如下： *生产基地研发及产业化项目已使用募集资金金额大 ...

A 股代码：688235 A 股简称：百济神州 公告编号：2023-036 港股代码：06160 港股简称：百济神州 美股代码：BGNE 百济神州有限公司 关于使用部分超募资金永久补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、百济神州有限公司（以下简称"公司"）董事会于2023年11月10日审议 通过《关于使用部分超募资金永久补充流动资金的议案》，同意公司使用部分超 募资金人民币48,900.00万元用于永久补充流动资金（以下简称"本次补流"）。 2、公司用于永久补充流动资金的超募资金在十二个月内的累计使用金额不 超过超募资金总额的30%，不会影响募集资金投资项目的建设资金需求，且公司 承诺在本次补流后的十二个月内不进行高风险投资以及为除全资、控股子公司或 控制的其他主体以外的第三方对象提供财务资助。 3、公司联席保荐机构中国国际金融股份有限公司与高盛（中国）证券有限 责任公司对本次补流出具了明确的核查意见。 4、本次补流已经公司董事会审议通过，根据《上海证券交易所科创板股票 上市 ...

A股代码：688235 A股简称：百济神州 公告编号：2023-037 港股代码：06160 港股简称：百济神州 美股代码：BGNE 百济神州有限公司 关于调整部分募投子项目募集资金投资金额的公告 （二）募集资金使用情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承 担法律责任。 重要内容提示： 1、百济神州有限公司（以下简称"公司"）首次公开发行人民币普通 股（A 股）股票募集资金（以下简称"首次发行募集资金"）投资项目"药 物临床试验研发项目"中包含临床阶段研发项目外部费用、临床阶段研发 项目内部费用、临床阶段研发项目材料费用以及临床前研究费用四项子 项目（以下合称"子项目"）。 2、为保证公司创新药的研发进度，提高募集资金使用效率，公司拟 根据药物临床试验研发进展、资金安排对子项目拟投入的募集资金金额 进行调整（以下简称"本次调整"）。本次调整不涉及药物临床试验研发 项目的总投资金额以及拟投入的募集资金总额的调整。 3、公司董事会于 2023 年 11 月 10 日审议通过了公司关于调整部分 募投子项目募集资金投资金额的决议。 ...

A 股代码：688235 A 股简称：百济神州 公告编号：2023-035 港股代码：06160 港股简称：百济神州 美股代码：BGNE 百济神州有限公司 关于公司为子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、被担保人： BeiGene Switzerland GmbH（以下简称"百济神州瑞士"）， 系百济神州有限公司（以下简称"公司"）的全资子公司。 2、本次担保金额及已实际为其提供的担保余额：公司拟为百济神州瑞士向 HSBC Continental Europe 申请的 1,200,000 欧元信贷额度（以下简称"本次信 贷"）提供担保（以下简称"本次担保"），并拟与 HSBC Continental Europe 就本次担保签署《保函》。截至本公告披露日，公司为百济神州瑞士提供的担 保余额为 0 元。 3、本次担保无反担保。 4、本次担保无需提交公司股东大会审议。 一、担保情况概述 （一）担保基本情况 （二）履行的内部决策程序 公司董事会于 2023 年 11 月 10 ...

中国国际金融股份有限公司、高盛（中国）证券有限责任公司 经中国证券监督管理委员会于 2021 年 11 月 16 日发布的《关于同意百济神 州有限公司首次公开发行股票注册的批复》（证监许可[2021]3568 号）批准，公 司首次公开发行人民币普通股（A 股）股票（以下简称"本次发行"）115,055,260 股，每股发行价格为人民币 192.60 元，募集资金总额为人民币 2,215,964.31 万 元；扣除发行费用后实际的募集资金净额为人民币 2,163,015.49 万元（其中，本 次发行的超募资金为人民币 163,015.49 万元）。上述募集资金已于 2021 年 12 月 8 日全部到位，安永华明会计师事务所（特殊普通合伙）对公司本次发行的募集 资金到位情况进行了审验，并于 2021 年 12 月 8 日出具了安永华明（2021）验字 第 61119809_A03 号《验资报告》。 为规范公司募集资金管理和使用，保护投资者权益，公司设立了相关募集资 金专项账户。募集资金到账后，已全部存放于经公司董事会或董事会审计委员会 批准开设的募集资金专项账户内，公司已与联席保荐机构和存放募集资金的商业 银行 ...

一、担保情况概述 （一）担保基本情况 为满足百济神州之全资子公司 BeiGene Switzerland GmbH（以下简称"百济 神州瑞士"）生产经营和业务发展的需求，百济神州瑞士拟向 HSBC Continental Europe 申请 1,200,000 欧元信贷额度（以下简称"本次信贷"）。公司拟与 HSBC Continental Europe 签署《保函》，为百济神州瑞士的本次信贷及相应利息和所有 其他费用无偿提供保证担保（以下简称"本次担保"）。 中国国际金融股份有限公司、高盛（中国）证券有限责任公司 关于百济神州有限公司为子公司提供担保事项的核查意见 中国国际金融股份有限公司与高盛（中国）证券有限责任公司（以下与中国 国际金融股份有限公司合称"联席保荐机构"）作为百济神州有限公司（以下简称 "百济神州"或"公司"）首次公开发行人民币普通股（A股）股票并在科创板上市 的联席保荐机构，根据《上海证券交易所科创板股票上市规则》《上海证券交易 所科创板上市公司自律监管指引第1号——规范运作》《上市公司监管指引第8号 ——上市公司资金往来、对外担保的监管要求》等有关规定，对百济神州为子公 司提供担保事项 ...

A 股代码：688235 A 股简称：百济神州 公告编号：2023-034 港股代码：06160 港股简称：百济神州 美股代码：BGNE 百济神州有限公司 截至2023年9月30日止三个月及九个月 主要财务数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 特别提示： 本公告所载的百济神州有限公司（以下简称"百济神州"或"公司"）截至 2023 年 9 月 30 日止三个月及九个月主要财务数据为初步核算数据，未经会计师事 务所审计，具体数据以公司 2023 年第三季度报告中披露的数据为准，提请投资者注 意投资风险。 本公告财务数据按中国企业会计准则编制并呈列。 本公司已于 2023 年 11 月 9 日（美国东部时间）同步发布了根据美国公认会 计原则及美国证券交易委员会适用规则编制的截至 2023 年 9 月 30 日止三个月及九 个月未经审计财务业绩，提请投资者注意与本公告区别。 1 一、主要财务数据和指标 单位：人民币千元 | | | 本报告期比上 | 年初至报告 | 年初至报告期 末比上年同期 | | --- ...